留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

高密度脂蛋白与系统性红斑狼疮早发动脉粥样硬化

丁发明 张抒扬

丁发明, 张抒扬. 高密度脂蛋白与系统性红斑狼疮早发动脉粥样硬化[J]. 协和医学杂志, 2017, 8(1): 50-55. doi: 10.3969/j.issn.1674-9081.2017.01.012
引用本文: 丁发明, 张抒扬. 高密度脂蛋白与系统性红斑狼疮早发动脉粥样硬化[J]. 协和医学杂志, 2017, 8(1): 50-55. doi: 10.3969/j.issn.1674-9081.2017.01.012

高密度脂蛋白与系统性红斑狼疮早发动脉粥样硬化

doi: 10.3969/j.issn.1674-9081.2017.01.012
详细信息
    通讯作者:

    张抒扬 电话: 010-69156802,E-mail:pumchzhangsy@163.com

  • 中图分类号: R543.3;R593.24

  • [1] 中华医学会风湿病学分会.系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志, 2010, 14: 342-346. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhfsbx98201005016
    [2] Rahman A, Isenberg DA. Systemic lupus erythematosus[J]. N Engl J Med, 2008, 358: 929-939. doi:  10.1056/NEJMra071297
    [3] Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus[J].Am J Med, 1976, 60: 221-225. doi:  10.1016/0002-9343(76)90431-9
    [4] Hansson GK, Hermansson A. The immune system in atherosclerosis [J]. Nat Immunol, 2011, 12: 204-212.
    [5] Hafiane A1, Kellett S, Genest J. Treatment options for low high-density lipoproteins[J]. CurrOpinEndocrinol Diabetes Obe, 2014, 21:134-139.
    [6] Karlsson H, Leanderson P, Tagesson C, et al. Lipoproteomics Ⅱ: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry [J]. Proteomics, 2005, 5:1431-1445. doi:  10.1002/pmic.200401010
    [7] Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL [J]. J Clin Invest, 2007, 117: 746-756. doi:  10.1172/JCI26206
    [8] Birner-Gruenberger R, Schittmayer M, Holzer M, et al. Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology [J]. Prog Lipid Res, 2014, 56:36-46. doi:  10.1016/j.plipres.2014.07.003
    [9] Norata GD, Pirillo A, Ammirati E, et al. Emerging role of high density lipoproteins as a player in the immune system [J]. Atherosclerosis, 2012, 220: 11-21. doi:  10.1016/j.atherosclerosis.2011.06.045
    [10] Dietrich C, Volovyk ZN, Levi M, et al. Partitioning of Thy-1, GM1, and cross-linked phospholipid analogs into lipid rafts reconstituted in supported model membrane monolayers [J]. Proc Natl Acad Sci USA, 2001, 98: 10642-10647. doi:  10.1073/pnas.191168698
    [11] Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J]. Nature, 2010, 464: 1357-1361. doi:  10.1038/nature08938
    [12] Hai T, Wolford CC, Chang AY-S. ATF3, a Hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? [J]. Gene Exp, 2010, 15:1-11. doi:  10.3727/105221610X12819686555015
    [13] Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type Ⅰ interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide [J]. Circulation, 2010, 122: 1919-1927. doi:  10.1161/CIRCULATIONAHA.110.961193
    [14] Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex [J]. J Clin Invest, 2013, 123: 3815-3828. doi:  10.1172/JCI67478
    [15] Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis [J]. Nat Med, 2013, 19: 586-594. doi:  10.1038/nm.3150
    [16] Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti- and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling [J]. Circulation, 2013, 127: 891-904. doi:  10.1161/CIRCULATIONAHA.112.108753
    [17] Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE: mechanisms and management [J]. Nat Rev Rheumatol, 2012, 8: 214-223. doi:  10.1038/nrrheum.2012.14
    [18] Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus [J]. Ann Rheum Dis, 2014, 73: 609-615. doi:  10.1136/annrheumdis-2012-202914
    [19] Smith CK, Vivekanandan-Giri A, Tang C, et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus [J]. Arthritis Rheumatol, 2014, 66: 2532-2544. doi:  10.1002/art.38703
    [20] McMahon M, Skaggs BJ, Sahakian L, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids [J]. Ann Rheum Dis, 2011, 70: 1619-1624. doi:  10.1136/ard.2010.142737
    [21] McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus [J]. Arthritis Rheumatol, 2014, 66: 130-139. doi:  10.1002/art.38204
    [22] Skaggs BJ, Hahn BH, SahakianL, et al. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFR beta, chemotaxis and TNF alpha production [J]. Clin Immunol, 2010, 137: 147-156. doi:  10.1016/j.clim.2010.06.014
    [23] Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis [J]. Arthritis Res Ther, 2008, 10: 213. doi:  10.1186/ar2471
    [24] Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome [J]. JAMA, 2009, 302: 1210-1217. doi:  10.1001/jama.2009.1346
    [25] Srivastava R, Yu S, Parks BW, et al. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice [J]. Arthritis Rheumatol, 2011, 63: 201-211. doi:  10.1002/art.27764
    [26] Tripi LM, Manzi S, Chen Q, et al. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus [J]. Arthritis Rheumatol, 2006, 54: 1928-1939. doi:  10.1002/art.21889
    [27] Marsillach J, Becker JO, Vaisar T, et al. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis [J]. J Proteome Res, 2015, 14: 2046-2054. doi:  10.1021/pr5011586
    [28] Parra S, Vives G, Ferre R, et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients [J]. Atherosclerosis, 2012, 225: 224-230. doi:  10.1016/j.atherosclerosis.2012.08.029
    [29] Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice [J]. Arterioscler Thromb Vasc Biol, 2005, 25: 1932-1937. doi:  10.1161/01.ATV.0000174589.70190.e2
    [30] Woo JM, Lin Z, Navab M, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis [J]. Arthritis Res Ther, 2010, 12: R93. doi:  10.1186/ar3020
    [31] Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-Ⅰ and high-density lipoprotein cholesterol in vitro and in vivo [J]. J Am Coll Cardiol, 2010, 55: 2580-2589. doi:  10.1016/j.jacc.2010.02.035
    [32] Goswami B, Rajappa M, Singh B, et al. Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease [J]. Cardiovasc J Afr, 2010, 21: 103-108.
    [33] Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-Ⅰ(Milano) mutant: the Limonesul Garda study[J]. Circulation, 2001, 103: 1949-1954. doi:  10.1161/01.CIR.103.15.1949
    [34] Ibanez B, Vilahur G, Cimmino G, et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-Ⅰ Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis [J]. J Am Coll Cardiol, 2008, 51: 1104-1109. doi:  10.1016/j.jacc.2007.09.071
    [35] Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial [J]. JAMA, 2007, 297: 1675-1682. doi:  10.1001/jama.297.15.jpc70004
    [36] Hovingh GK, Smits LP, Stefanutti C, et al. Effects of CER-001 on carotid atherosclerosis by 3TMRI in homozygous familial hypercholesterolaemia (HOFH): themodifying orphan disease evaluation (MODE) study [J]. Am Heart J, 2015, 169: 736-742. doi:  10.1016/j.ahj.2015.01.008
  • 加载中
计量
  • 文章访问数:  151
  • HTML全文浏览量:  6
  • PDF下载量:  193
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-16
  • 刊出日期:  2017-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!